The medical records of 8 consecutive patients with terminal urological cancers who were treated with implanted venous reservoirs between October 2001 and July 2004 were retrospectively reviewed. All 8 devices were placed safely in the 8 patients, and fluids and drugs were easily administered via the reservoirs. The devices were utilized for a mean of 40.6 days (range, 18 to 98) until the patients died of the cancer, and there were no complications which required removal of the devices such as catheter or reservoir infections, catheter occlusions and catheter thromboses. Seven patients were discharged or stayed at home on weekends and received home parental nutrition (HPN) through implanted venous reservoirs. Although HPN with the implanted venous reservoir is recently becoming common in digestive surgery or gynecological fields, it still remains uncommon in the urological field. Because this device would be useful and safe for patients with terminal urological cancers, we should consider the use of implanted venous reservoirs for patients who desire terminal home care.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Jugular Vascular Closure and Scar Formation after Leadless Pacemaker Implantation.
Rev Cardiovasc Med
December 2024
Department of Cardiology, Erasmus Medical Center, 3015GD Rotterdam, The Netherlands.
Background: Achieving hemostasis of large bore venous access sites can be challenging and time consuming. Closure devices have proven to be superior in achieving hemostasis, reducing time to ambulation and improving patient comfort, compared to manual hemostasis techniques after femoral venous and arterial access. The closure of the jugular vein following large bore access has not been investigated in previous studies.
View Article and Find Full Text PDFEfficacy and Safety of Low Molecular Weight Heparin and Mechanical Thromboprophylaxis in Immediate Implant-based Breast Reconstruction: A Retrospective Comparative Analysis.
In Vivo
December 2024
Department of Plastic, Reconstructive, and Aesthetic Surgery, Geneva University Hospitals, Geneva University, Geneva, Switzerland;
Background/aim: Low molecular weight heparin (LMWH) is widely employed to prevent postoperative venous thromboembolism (VTE). This study aimed at analyzing LMWH use and evaluating its efficacy and safety in immediate implant-based post-mastectomy breast reconstruction.
Patients And Methods: A monocentric retrospective analysis was conducted on patients who underwent immediate implant-based breast reconstruction (IBR) from January 2021 to December 2023.
Ultrasound-Guided Axillary Vein Puncture Versus Landmark-Guided Approach for Cardiac Implantable Electronic Device Placement.
Pacing Clin Electrophysiol
December 2024
Department of Cardiovascular Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Introduction: Ultrasound (US)-guided axillary vein puncture is a safe and effective approach for cardiac implantable electronic device (CIED) implantation, and it is highly recommended by the current consensus document. However, only reports on small populations are available in the current literature regarding the comparison of this technique with other traditional approaches (subclavian vein blind puncture and cephalic vein surgical cutdown).
Purpose: We aimed to assess the effectiveness and safety of US- guided axillary vein puncture using a microintroducer kit for CIED implantation as compared to the aforementioned traditional approaches.
Efficacy and Safety in the Implantation of Totally Implantable Venous Access Devices by Anesthesiologists: Perspectives From a Retrospective Oncology Cohort.
Cureus
November 2024
Anesthesiology, Anesthesia Unit, National Cancer Institute, Santiago, CHL.
Background: Totally implantable venous access devices (TIVADs) are widely used in oncology patients to facilitate central venous access. Although they offer benefits, TIVADs can be associated with complications.
Materials And Methods: This retrospective cohort study included all oncology patients 18 years or older who underwent TIVAD implantation between September 2015 and October 2019.
Factors associated with morbidity of a totally implantable venous access device in patients with breast cancer.
Turk J Med Sci
December 2024
Division of General Surgery, Department of Surgery, Institute of Oncology, İstanbul University, İstanbul, Turkiye.
Background/aim: To investigate the possible morbidities associated with the implantation of a totally implantable venous access device (TIVAD) in breast cancer (BC) patients.
Materials And Methods: Clinical data and developed complications in 546 BC patients with TIVAD between 2017 and 2021 were analyzed retrospectively. Among these, 524 (96%) patients who underwent TIVAD implantation via the right subclavian vein (SCV) route were examined separately.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!